Compound library / Research / Investigational
Chimeric peptide combining a p53-derived sequence with a cell-penetrating "penetratin" sequence, designed to selectively rupture cancer cell membranes via HDM-2 targeting in lab studies.
| Category | Research / Investigational |
|---|---|
| Typical route | Subcutaneous |
| Half-life | Not well characterized in humans |
| Common dose range | Research-stage only — no established human dosing; in-vitro/animal compound |
| Typical cycle length | Not established |
BioHack Track models PNC-27 at a half-life of 1 hours, so every dose you log is decayed against that curve and the app shows what is still circulating — not just what you typed.
Reconstitute with bacteriostatic water.
Refrigerate after reconstitution.
Laboratory/preclinical oncology research compound — self-administering an experimental anticancer peptide outside a clinical trial carries serious, unquantified risk.
Track PNC-27 in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.
These open a search of each database for PNC-27 — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.
General reference compiled for use inside the app, not medical advice and not a recommendation to take anything. Dose ranges are what is commonly discussed, not a prescription. Talk to a qualified healthcare professional.